Prognostic correlation of HLA-DR expression in large cell lymphoma as determined by LN3 antibody staining. An eastern cooperative oncology group (ECOG) study
- 15 September 1990
- Vol. 66 (6) , 1147-1153
- https://doi.org/10.1002/1097-0142(19900915)66:6<1147::aid-cncr2820660612>3.0.co;2-z
Abstract
Several previous studies employing surface-marker techniques suggest that HLA-DR antigen expression may correlate with prognosis in diffuse large cell lymphoma. Control studies in the authors' laboratory indicated that LN3 positivity in paraffinembedded tissue correlates well with HLA-DR antigen expression. Accordingly they examined 212 cases of diffuse large cell lymphoma from one of Eastern Cooperative Oncology Group's (ECOG) high-grade malignant lymphoma treatment protocols. All patients studied had careful clinical follow-up of between 5 and 11 1/2 years from diagnosis and initiation of therapy. There was no correlation of strongly positive, positive, weakly positive, equivocal, or negative staining with survival. Cases that were LN3 negative had a median survival of 18.8 months versus a median survival of 39.4 months for all LN3-positive cases. However this difference was not statistically significant when using a log-rank test. The authors were unable to confirm that HLA-DR antigen expression, as defined by LN3, is prognostically valuable in diffuse large cell lymphoma in a multi-institutional study.This publication has 8 references indexed in Scilit:
- THE ABERRANCY OF IMMUNOPHENOTYPE AND IMMUNOGLOBULIN STATUS AS INDICATORS OF PROGNOSIS IN B-CELL DIFFUSE LARGE CELL LYMPHOMA1988
- HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma.Journal of Clinical Investigation, 1988
- Chemotherapy followed by consolidation radiation therapy for the treatment of clinical stage ii aggressive histologic type non-hodgkin's lymphomaCancer, 1988
- Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1987
- IMMUNOHISTOCHEMICAL ANALYSIS OF HUMAN LYMPHOMAS WITH MONOCLONAL-ANTIBODIES TO B-CELL AND IA ANTIGENS REACTIVE IN PARAFFIN SECTIONS1985
- National cancer institute sponsored study of classifications of non-hodgkin's lymphomas. Summary and description of a working formulation for clinical usageCancer, 1982
- Announcement of formation of: The lymphoma task force and pathology reference centerCancer, 1968
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958